Comparison of the Pain and Functional Improvement of Combined Extracorporeal Shockwave Therapy With or Without Intra-articular Hyaluronic Acid and Platelet-rich Plasma Injection on Advanced Osteoarthritis of the Knees.
Key facts
- Who runs it
- Chang Gung Memorial Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 48 people enrolled
- Started
- 4 Aug 2023
- Ended
- 27 Jun 2025
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Extracorporeal Shock Wave Therapy
- Normal Saline
- Hyaluronic Acid (HA)
- Platelet-Rich Plasma
- Record updated
- 15 September 2026
Who can take part
- Age
- 20 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients aged 20 years and older with phase II, III, or IV osteoarthritis of the knee. The phase of osteoarthritis of the knee is defined according to the Kellgren-Lawrence classification; phase II: Only slight narrowing of the joint cavity, with visible bone spurs; phase III: Numerous bone spurs, significant narrowing of the joint cavity, and subchondral cysts visible in the subchondral bone; phase IV: Larger and more prominent bone spurs, severe narrowing of the joint cavity, sclerosis of the subchondral bone, and even joint deformities
Who cannot take part
- Patients with arrhythmia or those with pacemakers
- Individuals with coagulation disorders
- Patients with chronic renal failure (glomerular filtration rate < 60)
- Patients with known allergies to hyaluronic acid, or those with infections or skin diseases
- Pregnant or breastfeeding women
- Patients with tumors
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This was a single group, double-blind, randomized clinical trial that enrolled 48 patients with Kellgren-Lawrence grade II to IV osteoarthritis of the knee. Patients were randomly assigned to three groups: Saline + ESWT (S+E group), High Platelet-Rich Plasma (PRP + ESWT (P+E group), and Hyaluronic Acid + ESWT (HA + ESWT (H+E group). All patients were followed for one year. Assessments included the Visual Analogue Scale (VAS), serum enzyme-linked immunosorbent assay (ELISA), knee X-ray and ultrasound examinations, and functional scores (WOMAC, KOOS, and IKDC).
The 3 groups in the trial
- ESWT+normal salinePlacebo, for comparison
Each group received ESWT treatment and an injection of Saline as a placebo to prevent participants from knowing they were in the control group.
Treatment: Extracorporeal Shock Wave Therapy and Normal Saline
- ESWT+Hyaluronic Acid(HA)Treatment being tested
This group of patients will receive ESWT and HA injections.
Treatment: Extracorporeal Shock Wave Therapy and Hyaluronic Acid (HA)
- ESWT+Platelet-Rich Plasma(PRP)Treatment being tested
This group of patients will receive ESWT and PRP injections.
Treatment: Extracorporeal Shock Wave Therapy and Platelet-Rich Plasma
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 15 September 2026